The published studies use different experimental conditions and endpoints. This article focuses on those measurements and reported findings rather than treating them as evidence of a general skin benefit. Explore GHK-Cu from Direct SARMs for research product information and specifications.
GHK-Cu Research Measurements
| Research Area | Measurement | Reported Research Focus |
|---|---|---|
| Fibroblast studies: | Collagen synthesis | Collagen production |
| Fibroblast studies: | Glycosaminoglycans | Extracellular matrix composition |
| Dermal fibroblasts: | MMP-2 and MMP-2 mRNA | Matrix metalloproteinase expression |
| Dermal fibroblasts: | TIMP-1 and TIMP-2 | Tissue inhibitor secretion |
| Experimental wounds: | Collagen, DNA, protein, and GAG content | Wound-tissue composition |
| Dermal fibroblasts: | TNF-α-dependent IL-6 secretion | Inflammatory signaling |
| Human skin models: | Peptide and copper permeation | Skin-barrier transport |
| Formulation studies: | Stability and degradation | Chemical stability |
| Liposome studies: | Particle size and encapsulation efficiency | Carrier characteristics |
GHK-Cu in Skin Research
GHK-Cu is a copper complex of the tripeptide glycyl-L-histidyl-L-lysine (GHK). GHK was isolated from human plasma, and early research examined its interaction with copper and its effects in experimental systems.
Subsequent studies examined specific endpoints in fibroblast cultures and experimental wounds. These included collagen synthesis, glycosaminoglycan production, extracellular matrix proteins and gene expression.
The evidence comes from different experimental systems, so findings from one study should not automatically be applied to another.
Collagen Synthesis Measurements
A 1988 study examined GHK-Cu in cultured fibroblasts and measured collagen synthesis. The researchers reported stimulation of collagen synthesis after GHK-Cu exposure.
The response began between 10⁻¹² and 10⁻¹¹ M and was greatest at 10⁻⁹ M. The increase was not explained by a change in cell number.
A separate study examined sulfated glycosaminoglycan synthesis in normal human fibroblasts. GHK-Cu produced a dose-dependent increase in total glycosaminoglycan synthesis. The researchers found greater production of extracellular dermatan sulfate and cell-associated heparan sulfate, while hyaluronic acid synthesis was not affected.
These experiments measured specific extracellular matrix components in cultured cells. They did not measure changes in human skin appearance or clinical outcomes.
MMP-2 and TIMP Measurements
A study in cultured dermal fibroblasts examined MMP-2 expression after GHK-Cu exposure.
GHK-Cu increased MMP-2 levels in conditioned media and increased MMP-2 mRNA expression. The researchers also measured TIMP-1 and TIMP-2 and reported increased secretion of both tissue inhibitors.
The study therefore examined several markers associated with extracellular matrix turnover within a fibroblast culture system.
Measurements in Experimental Wounds
Animal studies have examined GHK-Cu using experimental wound models and measured the composition of the resulting wound tissue.
In a rat wound-chamber study, researchers measured dry weight, total protein, DNA, collagen, elastin, glycosaminoglycans, and specific mRNAs for type I and type III collagen and TGF-β.
GHK-Cu produced concentration-dependent increases in dry weight, DNA, total protein, collagen, and glycosaminoglycan content. Type I and type III collagen mRNA also increased, while TGF-β mRNA did not.
Another rat wound study examined glycosaminoglycans and small proteoglycans. Measurements included collagen, glycosaminoglycans, decorin, and biglycan. GHK-Cu treatment increased decorin expression and altered the measured glycosaminoglycan composition.
These findings describe changes measured in experimental wound tissue. They do not establish that the same changes occur in humans.
TNF-α-Dependent IL-6 Measurements
GHK-Cu has also been examined in cultured human dermal fibroblasts using inflammatory signaling measurements.
One study investigated TNF-α-dependent IL-6 secretion. GHK-Cu decreased TNF-α-dependent IL-6 secretion in the cultured fibroblasts, with IL-6 measured using an ELISA assay.
This was a cell-culture experiment examining cytokine secretion under defined laboratory conditions.
GHK-Cu Skin Permeation
Skin-permeation studies have examined the movement and retention of GHK-Cu in human skin models.
One ex vivo study used isolated human skin layers to measure copper tripeptide penetration. The researchers examined isolated stratum corneum, epidermis, and dermatomed skin and calculated permeability coefficients and flux values.
The measured permeability varied between the different skin preparations, showing that the experimental skin layer used can affect the measured transport of GHK-Cu.
Microneedle-Assisted Permeation
A separate study examined whether microneedle pretreatment changed GHK-Cu penetration through human skin.
After 9 hours, 134 ± 12 nmol of peptide and 705 ± 84 nmol of copper permeated microneedle-treated human skin. Almost no peptide or copper permeated intact human skin under the same experimental conditions.
The study therefore provides a direct comparison between intact skin and skin that had been pretreated with microneedles.
GHK-Cu Formulation and Stability Studies
Preformulation research has examined the physicochemical properties of GHK-Cu relevant to dermal delivery.
One study measured solubility, distribution coefficients, stability, degradation and compatibility with formulation components. GHK-Cu was highly hydrophilic, with reported log D values between −2.38 and −2.49 across pH 4.5 to 7.4.
Under the tested stressed conditions, the complex was susceptible to hydrolytic cleavage under basic and oxidative conditions and, to a lesser extent, under acidic conditions. Mass spectrometry identified several degradation products.
The study also examined compatibility with carrier materials. GHK-Cu was compatible with Span 60-based niosomes but showed lower stability with the negatively charged lipid dicetyl phosphate.
GHK-Cu-Loaded Liposome Studies
Researchers have also prepared liposomes containing GHK-Cu and measured their physicochemical properties.
A 2023 study examined anionic and cationic hydrogenated-lecithin liposomes containing GHK-Cu. Measurements included particle size, lipid composition, bilayer fluidity, and peptide encapsulation efficiency.
The study produced GHK-Cu-loaded liposomes with sizes of approximately 100 nm. Reported encapsulation efficiencies for selected formulations were 31.7 ± 0.9% for one cationic formulation and 20.0 ± 2.8% for one anionic formulation.
These findings establish that GHK-Cu can be incorporated into the tested liposomal systems and that their physical properties can be measured. They do not by themselves establish improved GHK-Cu penetration through human skin.
Limitations of the Current Evidence
The published GHK-Cu literature uses different cell systems, animal models, skin preparations, formulations, concentrations, exposure periods, and measurement methods.
A collagen-synthesis result from cultured fibroblasts therefore answers a different research question from a skin-permeation experiment or an animal wound study.
The same applies to formulation studies. Measurements of particle size, encapsulation efficiency, or chemical stability do not establish biological effects in humans.
These differences limit direct comparison between studies and make it inappropriate to combine all reported findings into a single measure of GHK-Cu skin activity.
Current Evidence on GHK-Cu Skin Research
Research on GHK-Cu has examined specific biological and formulation-related measurements rather than one single outcome.
The published evidence includes collagen and glycosaminoglycan synthesis in fibroblasts, MMP-2 and TIMP measurements, inflammatory cytokine secretion, composition of experimental wound tissue, skin permeation, chemical stability, and liposome characteristics.
The findings provide experimental data across several research areas. The strength and relevance of each finding depend on the model, formulation, concentration, and endpoint used in the individual study.
FAQs
References
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. PubMed ↗
- Pickart L, Vasquez-Soltero JM, Margolina A. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxid Med Cell Longev. 2012;2012:324832. PubMed ↗
- Dou Y, Lee A, Zhu L, Morton J, Ladiges W. The potential of GHK as an anti-aging peptide. Aging Pathobiol Ther. 2020 Mar 27;2(1):58-61. PubMed ↗
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK and DNA: resetting the human genome to health. Biomed Res Int. 2014;2014:151479. PubMed ↗
- Maquart FX, Bellon G, Chaqour B, Wegrowski J, Patt LM, Trachy RE, Monboisse JC, Chastang F, Birembaut P, Gillery P, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest. 1993 Nov;92(5):2368-76. PubMed ↗
- Gruchlik A, Jurzak M, Chodurek E, Dzierzewicz Z. Effect of Gly-Gly-His, Gly-His-Lys and their copper complexes on TNF-alpha-dependent IL-6 secretion in normal human dermal fibroblasts. Acta Pol Pharm. 2012 Nov-Dec;69(6):1303-6. PubMed ↗
